Overview
Biocon Biologics is a fully integrated, global biosimilars enterprise committed to making life-changing medicines affordable and accessible to patients everywhere. Guided by our purpose-driven mission to improve global health, and the courage to lead with conviction, we pursue a bold ambition: making essential therapies available to all who need them.
Lab-to-Patient Model with Global Scale
Our end-to-end, lab-to-patient model spans research, development, manufacturing, and commercialization—enabling us to address unmet medical needs and improve healthcare outcomes for patients in over 120 countries around the world. With world-class manufacturing facilities in India and Malaysia and a robust external manufacturing network, we are uniquely equipped to consistently and reliably deliver high-quality medicines to patients worldwide.
Solving Pressing Health Challenges
Patients are at the center of everything we do and hence our focus is on diseases that affect billions of people globally—diabetes, cancer, autoimmune conditions, serious eye disorders, and bone health. We deliver biosimilars that meet the highest global quality standards. Our portfolio includes 10 commercialized biosimilars and a strong pipeline of future launches.
Driving Affordable Innovation
We harness the power of the latest technologies to advance affordable innovation-while upholding the highest quality standards.
Our highly skilled teams apply advanced analytics, automation, robotics, and AI to optimize every stage of our operations—from R&D to manufacturing—ensuring consistency, compliance, and efficiency. These technologies and our deep expertise empower us to meet evolving market needs while keeping patients at the center of our efforts.
Our deep expertise is reflected in our pioneering achievements, including being the first to receive U.S. FDA approval for biosimilar Trastuzumab, followed by approvals for Pegfilgrastim, interchangeable Insulin Glargine, Aflibercept, and Insulin Aspart.
Committed to Sustainability
At Biocon Biologics, we are deeply committed to driving positive social and environmentally sustainable impact for a healthier world. Our inclusion in the S&P Global Sustainability Yearbook 2025 shows that we are among the top 15% of biotechnology companies worldwide with strong Environmental, Social, and Governance (ESG) practices.
Biocon Biologics: Milestones in the Biosimilars Journey
2025: Yesafili, biosimilar aflibercept, becomes the 10th biosimilar to be commercialized worldwide by Biocon Biologics.
2025: Yesintek, biosimilar ustekinumab, receives marketing approval in EU, UK and Japan.
2025: Kirsty is approved by the U.S. FDA as the first and only interchangeable rapid-acting insulin aspart.
2025: Biosimilar versions of denosumab for treating osteoporosis and cancer-related bone conditions are approved in the U.S., EU and UK.
2024: Biocon Biologics emerges as a fully integrated global biosimilars leader, and crosses the USD 1 billion revenue milestone.
2024: Yesafili is approved by the U.S. FDA as the first interchangeable biosimilar aflibercept.
2024: Yesintek, biosimilar ustekinumab, is approved in the U.S.
2023: Successfully integrates acquired Viatris business globally, expanding commercial footprint to 120+ markets worldwide.
2023: Yesafili (aflibercept) receives marketing approval in EU.
2022: Biocon Biologics acquires Viatris’ global biosimilars business in a multi-billion-dollar deal.
2021: Semglee, biosimilar Insulin Glargine, receives a historic U.S. approval as the world’s first ‘interchangeable’ biosimilar product.
2021: Kirsty (insulin aspart) and Abevmy (bevacizumab) receive marketing approvals in Europe.
2020: Nepexto (etanercept) receives marketing approval in Europe.
2019: Biocon’s Biosimilars business is consolidated under an independent entity – Biocon Biologics Limited – with its dedicated management.
2018: Fulphila becomes the first biosimilar pegfilgrastim to be approved in the U.S.
2018: Ogivri (trastuzumab), Fulphila (pegfilgrastim), Semglee (insulin glargine), and Hulio (adalimumab) receive marketing approvals in EU.
2017: Ogivri becomes the first biosimilar trastuzumab to be approved in the U.S.
2016: Biocon becomes the first company from India to have a biosimilar approved and commercialized in Japan following the regulatory nod to insulin glargine.
2014: Launches the world’s first approved biosimilar version of trastuzumab in India.
2004: Biocon is the first and only company in the world to commercialize a Pichia pastoris-derived recombinant human insulin.
2000: Biocon is among the first Indian companies to envision a biosimilars-led future, initiating efforts to build capabilities for developing affordable, high-quality biosimilar therapies.
Biocon Biologics sets global benchmarks with its expertise in biosimilar mAbs and conjugated proteins for treating diabetes, cancer, autoimmune, ophthalmic, bone, and other non-communicable diseases.
With one of the deepest pipelines, scientific and regulatory expertise, and continued investment in world-class facilities and talent, we focus on differentiated R&D, advanced manufacturing, and a robust commercial network to deliver affordable biologics, better care, and greater hope globally.
Global Presence
Biocon Biologics has a strong presence in advanced markets across North America (U.S. & Canada), Europe, and JANZ (Japan, Australia, New Zealand), with a robust biosimilars portfolio in diabetes, oncology, and immunology, gaining solid brand equity and market share.
In Emerging Markets, covering 80+ countries and 70% of our patient base, we leverage flexible models to maximize reach across AFMET (Africa, Middle East, Turkey), APAC, and LATAM.
